- Home
- RIGL vs UPXI Comparison
RIGL vs UPXI Comparison
Compare RIGL & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- UPXI
- Stock Information
- Founded
- RIGL 1996
- UPXI 2018
- Country
- RIGL United States
- UPXI United States
- Employees
- RIGL N/A
- UPXI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- RIGL Health Care
- UPXI Health Care
- Exchange
- RIGL Nasdaq
- UPXI Nasdaq
- Market Cap
- RIGL 335.5M
- UPXI 481.8M
- IPO Year
- RIGL 2000
- UPXI 2021
- Fundamental
- Price
- RIGL $38.85
- UPXI $7.23
- Analyst Decision
- RIGL Buy
- UPXI
- Analyst Count
- RIGL 5
- UPXI 0
- Target Price
- RIGL $38.20
- UPXI N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- UPXI 8.1M
- Earning Date
- RIGL 08-05-2025
- UPXI 05-16-2025
- Dividend Yield
- RIGL N/A
- UPXI N/A
- EPS Growth
- RIGL N/A
- UPXI N/A
- EPS
- RIGL 5.43
- UPXI N/A
- Revenue
- RIGL $267,921,000.00
- UPXI $16,562,327.00
- Revenue This Year
- RIGL $59.93
- UPXI $299.03
- Revenue Next Year
- RIGL N/A
- UPXI N/A
- P/E Ratio
- RIGL $7.15
- UPXI N/A
- Revenue Growth
- RIGL 105.62
- UPXI 1378.83
- 52 Week Low
- RIGL $12.66
- UPXI $1.90
- 52 Week High
- RIGL $43.72
- UPXI $22.57
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- UPXI 51.85
- Support Level
- RIGL $39.00
- UPXI $6.16
- Resistance Level
- RIGL $42.08
- UPXI $9.12
- Average True Range (ATR)
- RIGL 2.32
- UPXI 0.97
- MACD
- RIGL -0.37
- UPXI 0.10
- Stochastic Oscillator
- RIGL 53.26
- UPXI 47.86
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.